文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

造血干细胞移植后免疫介导性贫血:文献综述与新型治疗

Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.
PubMed 文献 · Blood Adv · 2022-01-01

异基因造血干细胞移植(HSCT)后贫血可为免疫或非免疫介导,血型不合导致的自身或同种免疫是重要原因。本文综述ABO及非ABO血型不合相关移植后免疫介导性贫血的机制、时间关联及防治方法,并介绍新型治疗。

要点

  • ABO血型不合在HSCT中常见,可导致急性溶血、纯红细胞再生障碍及过客淋巴细胞综合征等严重并发症。
  • ABO血型不合是否影响HSCT结局(复发、非复发死亡、移植物抗宿主病及生存)仍存争议。
  • 非ABO血型不合较少见但可导致类似并发症,识别移植后贫血的驱动病因对防治至关重要。

核心结论

  • 识别移植后贫血的驱动病因对预防和治疗至关重要,需全面理解血型不合HSCT中贫血的机制及HSCT与贫血的时间关联。

研究设计与样本

  • 文献综述,聚焦ABO及非ABO血型不合相关的移植后免疫介导性贫血。

主要发现

  • ABO血型不合在HSCT中常见,可导致急性溶血、纯红细胞再生障碍及过客淋巴细胞综合征等严重临床并发症。
  • ABO血型不合是否影响HSCT结局(如复发、非复发死亡、移植物抗宿主病及生存)仍存争议。
  • 非ABO血型不合较少见,但可导致与ABO血型不合类似的并发症,造成不良临床结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia after allogeneic hematopoietic stem cell transplantation (HSCT) can be immune or non-immune mediated. Auto- or alloimmunity resulting from blood group incompatibility remains an important cause in post-HSCT immune-mediated anemia. ABO incompatibility is commonly encountered in HSCT and may lead to serious clinical complications, including acute hemolysis, pure red cell aplasia, and passenger lymphocyte syndrome. It remains controversial whether ABO incompatibility may affect HSCT outcomes, such as relapse, nonrelapse mortality, graft-versus-host disease, and survival. Non-ABO incompatibility is less frequently encountered but can have similar complications to ABO incompatibility, causing adverse clinical outcomes. It is crucial to identify the driving etiology of post-HSCT anemia in order to prevent and treat this condition. This requires a comprehensive understanding of the mechanism of anemia in blood group-incompatible HSCT and the temporal association between HSCT and anemia. In this review, we summarize the literature on post-HSCT immune-mediated anemia with a focus on ABO and non-ABO blood group incompatibility, describe the underlying mechanism of anemia, and outline preventive and treatment approaches.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Migdady Y, Pang Y, Kalsi SS, et al. Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. Blood Adv. 2022. PMID: 34972204. doi:10.1182/bloodadvances.2021006279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。